Array BioPharma
| Nasdaq: ARRY Russell 2000 Component | |
| Founded | 1998  |
| Headquarters | , |
| Website | https://www.arraybiopharma.com/ |
Array BioPharma (Nasdaq: ARRY)[1] is a U.S.-based, clinical stage, publicly traded pharmaceutical company founded in Boulder, Colorado[2] that is included in the NASDAQ Biotechnology Index.[3]
In June 2019, Pfizer announced it would acquire the business for $10.6 billion.[4]
History
The company has engaged in collaborations with Pfizer and Merck to study several cancer targeting drug combinations.[5][6] In July 2013 the company partnered with Loxo Oncology to develop cancer drugs[7], in November 2015 the company partnered with Pierre Fabre[8] and the company also partnered with Ono Pharmaceutical in March 2016 to test the combination of binimetinib and encorafenib while retaining commercialization rights in the U.S. and other markets.[9][10]
In 2017 it spun out one of its programs into a subsidiary called Yarra; the asset was a molecule called ARRY-797 that was in a Phase II trial for cardiomyopathy.[2]
In March 2018 Array sued AstraZeneca for breach of contract, saying that AZ owed it a 12% royalty on a portion of the $1.6 billion upfront payment that Merck had paid to AZ in a deal for selumetinib, which Array said it had licensed to AZ in 2003.[11]
In June 2018, the combination of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) was approved by the FDA for the treatment of people with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma.[12]
On September 20, 2018, Array BioPharma Inc. issued a press release announcing that the European Commission (EC) approved BRAFTOVI® in combination with MEKTOVI® for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation, as detected by a validated test. This approval is applicable to all 28 European Union (EU) member states, as well as Liechtenstein, Iceland and Norway.[13]
References
- ^ "Array BioPharma Inc. (ARRY)". NASDAQ.com. NASDAQ OMX Group. Retrieved 3 January 2016.
- ^ a b Castle, Shay (December 26, 2017). "Boulder's Array BioPharma spins out subsidiary to develop rare-disease drugs". The Denver Post.
- ^ "^NBI Components NASDAQ Biotechnology Stock - Yahoo! Finance". finance.yahoo.com. Yahoo Finance. Retrieved 5 June 2017.
- ^ https://uk.reuters.com/article/us-array-biopharma-m-a-pfizer/pfizer-makes-10-6-billion-cancer-bet-in-cash-deal-for-array-biopharma-idUKKCN1TI15T
- ^ Al Idrus, Amirah (December 19, 2017). "Array Biopharma ties up with Pfizer on cancer-fighting combos". =FierceBiotech.
{{cite news}}: CS1 maint: extra punctuation (link) - ^ Hughes, Emily (6 June 2016). "Merck, Pierre Fabre and Array BioPharma collaborate for cancer drug clinical trial". EPM Magazine.
- ^ "Array, Loxo Ink $434M+ Deal for Small Molecule Cancer Drug Development". Genetic Engineering News. July 10, 2013.
- ^ Lawrence, Stacy (September 26, 2016). "Array up by more than half on PhIII melanoma combo data". FierceBiotech.
- ^ Taylor, Phil (May 31, 2017). "Array adds Ono as Japanese partner for MEK/BRAF combo". FierceBiotechm.
- ^ Vinluan, Frank (June 1, 2017). "Array Lands $31M in Licensing Deal with Japan's Ono Pharma". Xconomy.
- ^ Vogt, RJ (March 19, 2018). "AstraZeneca Owes $192M For Cancer Drug Rights, Rival Says". Law360.
- ^ "Press release: FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations". FDA. June 27, 2018.
- ^ "Array Biopharma 8-K Filing with the SEC". Fintel.io. September 20, 2018.
 | This United States corporation or company article is a stub. You can help Wikipedia by expanding it. |
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |